[go: up one dir, main page]

CU20090226A7 - Derivados de n5-(2-etoxi-etil)-n3-(2-piridinil)-3,5-piperidin-dicarboxamida - Google Patents

Derivados de n5-(2-etoxi-etil)-n3-(2-piridinil)-3,5-piperidin-dicarboxamida

Info

Publication number
CU20090226A7
CU20090226A7 CU20090226A CU20090226A CU20090226A7 CU 20090226 A7 CU20090226 A7 CU 20090226A7 CU 20090226 A CU20090226 A CU 20090226A CU 20090226 A CU20090226 A CU 20090226A CU 20090226 A7 CU20090226 A7 CU 20090226A7
Authority
CU
Cuba
Prior art keywords
compound
treatment
class
dicarboxamida
piridinil
Prior art date
Application number
CU20090226A
Other languages
English (en)
Other versions
CU23842B1 (es
Inventor
Fumiaki Yokokawa
Atsushi Toyao
Masaki Susuki
Shimpei Kawakami
Osamu Irie
Yuko Hitomi
Takeru Ehara
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39926743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20090226(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20090226A7 publication Critical patent/CU20090226A7/es
Publication of CU23842B1 publication Critical patent/CU23842B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula I: ESPACIO PARA LA FÓRMULA en donde R1, R2, R3, R4 y R5 son como se definen en la memoria descriptiva, para utilizarse en el diagnóstico y el tratamiento terapéutico de un animal de sangre caliente, en especial para el tratamiento de una enfermedad (= trastorno) que dependa de la actividad de la renina; al uso de un compuesto de esta clase para la preparación de una formulación farmacéutica para el tratamiento de una enfermedad que dependa de la actividad de la renina; al uso de un compuesto de esta clase en el tratamiento de una enfermedad que dependa de la actividad de la renina; a formulaciones farmacéuticas de un compuesto de esta clase; a un método de tratamiento, el cual comprende administrar un compuesto de esta clase, y a un método para su fabricación.
CU2009000226A 2007-06-25 2009-12-22 Derivados de n5-(2-etoxi-etil)-n3-(2-piridinil)-3,5-piperidin-dicarboxamida CU23842B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07012412 2007-06-25
EP07111290 2007-06-28
PCT/EP2008/057964 WO2009000811A1 (en) 2007-06-25 2008-06-23 N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors

Publications (2)

Publication Number Publication Date
CU20090226A7 true CU20090226A7 (es) 2012-02-15
CU23842B1 CU23842B1 (es) 2012-10-15

Family

ID=39926743

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2009000226A CU23842B1 (es) 2007-06-25 2009-12-22 Derivados de n5-(2-etoxi-etil)-n3-(2-piridinil)-3,5-piperidin-dicarboxamida

Country Status (26)

Country Link
US (2) US8383650B2 (es)
EP (2) EP2527338B1 (es)
JP (1) JP5086433B2 (es)
KR (1) KR101238479B1 (es)
CN (1) CN101687847B (es)
AR (1) AR067132A1 (es)
AU (1) AU2008267287B2 (es)
BR (1) BRPI0813900A2 (es)
CA (1) CA2689109A1 (es)
CL (1) CL2008001872A1 (es)
CO (1) CO6251267A2 (es)
CR (1) CR11153A (es)
CU (1) CU23842B1 (es)
EA (1) EA016446B1 (es)
EC (1) ECSP099825A (es)
ES (2) ES2541107T3 (es)
GT (1) GT200900324A (es)
HN (1) HN2009003463A (es)
IL (1) IL202494A0 (es)
MA (1) MA31538B1 (es)
NZ (1) NZ582098A (es)
PE (1) PE20090425A1 (es)
SG (1) SG182223A1 (es)
TN (1) TN2009000530A1 (es)
TW (1) TWI404714B (es)
WO (1) WO2009000811A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527338B1 (en) 2007-06-25 2015-05-06 Novartis AG N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
US20180048921A1 (en) * 2016-08-12 2018-02-15 Microsoft Technology Licensing, Llc Real-time playback diagnostics

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA929788B (en) 1991-12-18 1993-06-22 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring.
IL111176A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
IL123293A (en) 1995-09-07 2003-06-24 Hoffmann La Roche Piperidine derivatives, their preparation and pharmaceutical compositions containing them
JP2000500502A (ja) 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
CA2298813A1 (en) 1997-08-28 1999-03-04 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6429213B1 (en) 1998-06-17 2002-08-06 Bristol Myers Squibb Pharma Co Cyclic hydroxamic acids as metalloproteinase inhibitors
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
AU747776B2 (en) 1998-10-30 2002-05-23 Merck & Co., Inc. Thrombin inhibitors
AU3389300A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
WO2000051607A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6303593B1 (en) 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2000063173A1 (en) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
JP2003528072A (ja) 2000-03-17 2003-09-24 ブリストル−マイヤーズ スクイブ ファーマ カンパニー マトリックスメタロプロテアーゼおよびＴＮＦ−αの阻害剤としての環状β−アミノ酸誘導体
FR2811673B1 (fr) 2000-07-17 2002-09-13 Rhodia Chimie Sa Utilisation de composes insatures comprenant un heterocycle comme stabilisants de polymeres halogenes
EP1326619A2 (en) 2000-10-11 2003-07-16 Merck & Co., Inc. Pyrrolidine modulators of ccr5 chemokine receptor activity
AU2002306848A1 (en) 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
WO2003024899A2 (en) 2001-09-17 2003-03-27 Bristol-Myers Squibb Company CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
BR0309498A (pt) 2002-04-29 2005-02-15 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças que são relacionadas com o ras, e, uso de compostos
ES2315568T3 (es) 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido.
EP1656368A4 (en) 2002-07-09 2009-08-26 Bristol Myers Squibb Co SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
AU2004234040A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
EP1620403B1 (en) 2003-04-29 2007-11-28 Actelion Pharmaceuticals Ltd. Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives
WO2004096799A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd Tropane derivatives and their use as ace inhibitors
JP2006524655A (ja) 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド ３−位にヘテロ原子を有する新規９−アザビシクロノネン誘導体
BRPI0409818A (pt) 2003-04-30 2006-05-09 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409882A (pt) 2003-05-02 2006-05-23 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
JP2007508260A (ja) 2003-10-09 2007-04-05 アクテリオン　ファマシューティカルズ　リミテッド 新規なテトラヒドロピリジン誘導体
EP2266951A1 (en) 2003-11-26 2010-12-29 Novartis AG Organic compounds
US20070078164A1 (en) 2003-11-26 2007-04-05 Richard Sedrani 4-Phenylpiperidine derivatives as renin inhibitors
CA2553836A1 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their use as renin inhibitors
WO2005070871A2 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their activity as renin inhibitors
DE602005022060D1 (de) 2004-01-23 2010-08-12 Novartis Ag Diaminoalkohole und deren verwendung als renininhibitoren
US7868036B2 (en) 2004-03-19 2011-01-11 Novartis Ag Organic compounds
ATE421501T1 (de) 2004-03-19 2009-02-15 Speedel Experimenta Ag 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
TW200613274A (en) 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
TW200631929A (en) 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) 2005-03-09 2005-04-13 Novartis Ag Organic compounds
WO2006095020A1 (en) 2005-03-11 2006-09-14 Speedel Experimenta Ag Heterocyclic-substituted alkanamides useful as renin inhibitors
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
AR053836A1 (es) 2005-03-31 2007-05-23 Speedel Experimenta Ag Piperdinas 3,4,5-sustituidas
GB0508992D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
PL1948654T3 (pl) 2005-09-17 2009-12-31 Novartis Ag Pochodne 5-amino-4-hydroksy-7-(imidazo [1,2-a] pirydyn-6-ylometylo)-8-metylononyloamidu i związki pokrewne jako inhibitory reniny do leczenia nadciśnienia
EP1937248B1 (en) 2005-09-17 2010-06-02 Novartis Ag Alcanoic acid amides substituted by saturated o-heterocycles
PE20071079A1 (es) * 2005-11-15 2007-12-16 Cytokinetics Inc Compuestos de piperidina como inhibidores de la proliferacion celular
JP5306821B2 (ja) * 2005-12-30 2013-10-02 ノバルティス アーゲー レニン阻害剤としての３，５−置換ピペリジン化合物
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
WO2007085651A1 (en) 2006-01-30 2007-08-02 Speedel Experimenta Ag Process for the stereoselective preparation of alcohols from alpha, beta- insaturated compounds
WO2007141318A1 (en) 2006-06-08 2007-12-13 Speedel Experimenta Ag 2,5-disubstituted piperidines
GB0611697D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
GB0611696D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
TW200831463A (en) 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
EP1908471A1 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
EP1921069A1 (de) 2006-11-08 2008-05-14 Speedel Experimenta AG Verfahren zur Herstellung von 2-Alkyl-3-heterocyclyl-prop-2-en-1-olen
WO2008113835A1 (en) 2007-03-21 2008-09-25 Novartis Ag Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one
EP2527338B1 (en) 2007-06-25 2015-05-06 Novartis AG N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors

Also Published As

Publication number Publication date
EP2181105A1 (en) 2010-05-05
AU2008267287A1 (en) 2008-12-31
PE20090425A1 (es) 2009-05-12
IL202494A0 (en) 2010-06-30
SG182223A1 (en) 2012-07-30
ECSP099825A (es) 2010-01-29
EP2181105B1 (en) 2015-04-29
JP5086433B2 (ja) 2012-11-28
WO2009000811A1 (en) 2008-12-31
TN2009000530A1 (en) 2011-03-31
US8497286B2 (en) 2013-07-30
TWI404714B (zh) 2013-08-11
CN101687847A (zh) 2010-03-31
AU2008267287B2 (en) 2012-02-16
CN101687847B (zh) 2013-11-06
CA2689109A1 (en) 2008-12-31
CR11153A (es) 2010-01-21
NZ582098A (en) 2012-03-30
ES2541107T3 (es) 2015-07-16
CO6251267A2 (es) 2011-02-21
AR067132A1 (es) 2009-09-30
KR101238479B1 (ko) 2013-03-04
HN2009003463A (es) 2012-12-10
JP2010531328A (ja) 2010-09-24
US20130005770A1 (en) 2013-01-03
EP2527338A1 (en) 2012-11-28
CL2008001872A1 (es) 2009-02-20
MA31538B1 (fr) 2010-07-01
ES2543641T3 (es) 2015-08-20
EA016446B1 (ru) 2012-05-30
EA201000037A1 (ru) 2010-06-30
GT200900324A (es) 2011-11-03
US8383650B2 (en) 2013-02-26
KR20100023003A (ko) 2010-03-03
BRPI0813900A2 (pt) 2014-12-30
US20080319018A1 (en) 2008-12-25
EP2527338B1 (en) 2015-05-06
TW200911782A (en) 2009-03-16
CU23842B1 (es) 2012-10-15

Similar Documents

Publication Publication Date Title
ECSP088587A (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
DOP2010000263A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met
ECSP099409A (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona, procedimientos para su preparación y su uso como agentes farmacéuticos
CL2007003289A1 (es) Compuestos derivados de biciclocarboxiamida; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades provocadas por la hiperactivacion del receptor vc1 como dolor, enfermedad de vejiga, inflam
GT200500359A (es) Compuestos organicos
UY30094A1 (es) Compuestos químicos
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
ECSP10010694A (es) DERIVADOS DE BENZOXAZINONA QUE ACTÚAN COMO AGONISTAS DE RECEPTORES ADRENÉRGICOS ß2 PARA EL TRATAMIENTO DE TRASTORNOS RESPIRATORIOS
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.
CU20120081A7 (es) Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
WO2010051196A8 (en) Novel substituted azabenzoxazoles
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
CU23842B1 (es) Derivados de n5-(2-etoxi-etil)-n3-(2-piridinil)-3,5-piperidin-dicarboxamida
CO6290762A2 (es) Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral
GT200500328A (es) Sal l-tartrato de n-1-adamantil-2-{3-[(2r)-2-({(2r)-2-hidroxi-2[4-hidroxi-3-(hidroximetil)fenil]etil}amino)propil]fenil}acetamida.
WO2009114136A3 (en) Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents
BRPI0606750A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e,composição farmacêutica
UY29832A1 (es) Derivados de 2-aminotiazoles y 2-aminooxazoles, procesos para su preparación y su uso como compuestos farmacéuticos.
WO2007144129A3 (en) Pyrrolidine derivatives useful against diseases that depends on activity of renin
UA99461C2 (en) N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
ECSP055984A (es) Derivados cicloalquilo que tienen grupos ácido carboxílico bioisostéricos, procesos para su preparación y su uso como composiciones farmacéuticas

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)